Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients
Status:
Withdrawn
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
Patients undergoing orthotopic liver transplant will experience some degree of clinical
and/or biochemical hepatic dysfunction. This early injury is known as primary graft
dysfunction and varies from minor abnormalities to primary nonfunction. Prostaglandin-class
drugs, including prostacyclin and its analogs, could represent an important advance toward
the goal of reducing transplant related morbidity, mortality and associated costs by
providing these benefits.